

Quality Improvement

ACoS Standard 4.6

Monitoring compliance with evidence-based treatment guidelines

Each year, a physician member of the cancer committee performs a study to assess whether patients within the program are evaluated and treated according to evidence-based national treatment guidelines. Study results are presented to the cancer committee and documented in the minutes. Cancer Program Standards 2012

The committee selected Dr. Wallace for review of prostate cancer. Two hundred forty-eight prostate cases were accessed by the registry in 2015. These cases were evaluated by a tool created using elements of the NCCN guidelines. The tool was approved by the cancer committee on 9/14/16.

Review: Two hundred and forty-eight cases were reviewed. Cases were evaluated for conformity with NCCN guidelines for evaluation and treatment.

Concordance with NCCN pre-treatment evaluation guidelines:

Pretreatment evaluation should include PSA, Gleason score, and clinical t stage. Cases were excluded if they were incidental findings during other urologic surgery or presented with metastatic disease. All remaining cases had PSAs and Gleason scores. Registrars documented staging deficiencies for clinical t stage for 42 cases (17%). Documentation may exist in records not available to the registry.

Concordance with treatment guidelines:

Eighty eight cases had high risk or very high risk disease (34%). Forty one of these patients had prostatectomy and lymph node dissection and were not evaluated for treatment with hormone therapy. All of the 43 high risk or very high risk patients treated with radiation alone were offered hormone therapy (100%). There were two documented refusals.